Cholangiocarcinoma Foundation 4 Fight Colorectal Cancer 6 GO2 Foundation for Lung Cancer 7 ICAN, NCCN Digital Booklet of Patient Advocacy Resources National Comprehensive Cancer Network, , A c c e s s i b l e , a n d Equitable Cancer Care The NCCN Digital Resource Booklet includes, to precision medicine and address related needs for people with cancer. This Booklet was developed in conjunction with The National Comprehensive Cancer Network’s ® (NCCN ® ) Virtual Patient
https://www.nccn.org/docs/default-source/oncology-policy-program/advocacy-december-toolkit_2021.pdf?sfvrsn=4c2c60da_1of patients with suspected or newly diagnosed lung cancer in Antelope Valley, one of the most underserved regions of Southern California. Antelope Valley has the highest rate of lung cancer mortality, of the first lung cancer screening program in Antelope Valley. This initiative has touched many, and treatment of lung cancer in this underserved area.” Dan J. Raz, MD City of Hope National Medical Center, that improve the lives of patients with cancer. National Comprehensive Cancer Network® Namrata Vijayvergia
https://www.nccn.org/docs/default-source/oncology-research-program-(orp)/nccn_oncology_research_program_brochure.pdf?sfvrsn=ebab0181_3cancer rather than a lung cancer patient ). An illness or disease is something individuals have (ie, Language Guide. International Association for the Study of Lung Cancer; 2021. Available at: https, Version 2.0 | April 25, 2025 © 2025 National Comprehensive Cancer Network® (NCCN®) NCCN, Guidance Version 2.0 April 25, 2025 Page 2 of 10 © 2025 National Comprehensive Cancer Network, Version 2.0 April 25, 2025 Page 3 of 10 © 2025 National Comprehensive Cancer Network® (NCCN
https://www.nccn.org/docs/default-source/about/nccn-guidance-on-inclusive-language.pdf?sfvrsn=53c8c78f_2, e.g.: …MCL, mantle cell lymphoma; NCCN, National Comprehensive Cancer Network; SCLC, small cell lung cancer; … Yes, you can include the NCCN abbreviation in an already ongoing list of abbreviations. It, broad statement such as "National guidelines recommend MMR biomarker testing for colorectal cancer, Comprehensive Cancer Network® (NCCN®),” please use “NCCN Recommendations”. However, if the mention, Comprehensive Cancer Network® (NCCN®)" How should we reference the Biomarkers Compendium? The NCCN
https://www.nccn.org/guidelines/submissions-licensing-and-permissions/permission-to-cite-or-use-nccn-content-faqat the IASLC 2025 World Conference on Lung Cancer Visit NCCN at table #4! EVENT, Philadelphia, PA Save the Date! NCCN 2025 Lung Cancer Congress Earn CE credit. | In-person, collective mission to define and advance quality, effective, equitable, and accessible cancer care, in Oncology (NCCN Guidelines®) Collaborate with other leading academic cancer centers and utilize NCCN, Resources | Patient Resources | Research Opportunities | Advancing Cancer Equity | CE
https://www.nccn.org/members/member-institution-portal/member-institution-toolkitof Resectable Non-Small Cell Lung Cancer 1.00 AAPA Category 1 CME credit 1.00 ACPE contact hours 1.00, $0.00 Patient Management Simulator: Treatment Recommendations for Kidney Cancer, Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes, • Phone: 215.690.0300 • Fax: 215.690.0280Copyright © 2025 National Comprehensive Cancer Network, All
https://www.nccn.org/education-research/continuing-education-(ce)/continuing-education, NCCN Panelists included: • Arun Krishna, PhD, Vice-President, US Franchise Head & Lung Cancer, featured on the panel. Dr. Krishna discussed the importance of lung cancer screening because the U.S., of 2023 entitled Cancer Across Geography which resulted in a subsequent JNCCN publication. Many of our, the Reducing Hereditary Cancer Act, among a variety of other federal pieces of legislation. NCCN, Guidelines® into law when appropriate, fertility preservation, access to hereditary cancer screening
https://www.nccn.org/docs/default-source/oncology-policy-program/nccn-sosf-2024-thirteenth-annual-summary.pdf?sfvrsn=5346b0f5_12021_Elevating_Cancer_Equity_Webinar_Slides, Prostate Cancer Lung Cancer 13 © National Comprehensive Cancer Network, Inc. 2021, All Rights, Prevalence Va r i e s G e o g raphically 2017 Medicare Population 25 Lung Cancer Prostate Cancer, 1 © National Comprehensive Cancer Network, Inc. 2021, All Rights Reserved. No part, or mechanical, without first obtaining written permission from NCCN ® . Elevating Cancer Equity: Recommendations to Reduce Racial Disparities in Guideline Adherent Cancer Care February 22, 2021
https://www.nccn.org/docs/default-source/oncology-policy-program/2021_elevating_cancer_equity_webinar_slides.pdf?sfvrsn=e11f66e4_4Cancers Submitted by Amgen Inc. on 12/15/2021 CEA level for Rectal Cancer Submitted, ctDNA testing for Colon/Rectal Cancers Submitted by Colorectal Cancer Alliance on 07/08/2022 ctDNA testing for Colon/Rectal Cancers Submitted by Fight Colorectal Cancer on 07/18/2022, by COLONTOWN on 07/21/2022 ctDNA testing for Colon/Rectal Cancers Submitted by Colon Cancer, + cetuximab for Colon/Rectal Cancers Submitted by Colorectal Cancer Alliance on 08/04/2023
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyinterested in giving toward specific areas of cancer (i.e. breast cancer, lung cancer, etc.) should, Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education—to empower people living with cancer and advance oncology innovation, and for adaptation of new Guidelines for additional cancer topics. Specific NCCN Guidelines, top next-generation cancer researchers, guiding the course of treatment innovation and advancement
https://www.nccn.org/patientresources/patient-resources/nccn-foundation/ways-to-giveof Resectable Non-Small Cell Lung Cancer 1.00 AAPA Category 1 CME credit 1.00 ACPE contact hours 1.00, $0.00 Patient Management Simulator: Treatment Recommendations for Kidney Cancer, Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes, • Phone: 215.690.0300 • Fax: 215.690.0280Copyright © 2025 National Comprehensive Cancer Network, All
https://www.nccn.org/lms_redirectfor clinicians and others who work with patients with cancer. A s a response to these ongoing challenges, help, search by cancer type or supportive care indication, drug name, or by reimbursement or assistance, and services at: NCCN.org/reimbursement Reimbursement Resource Guide National Comprehensive Cancer Network® National Comprehensive Cancer Network® Reimbursement Resource Guide NCCN.org/reimbursement, cancer patients. Practices and patients are assigned a dedicated Oncology Nurse Advocate who will seek
https://www.nccn.org/docs/default-source/business-policy/rrr-pdf-2021.pdf?sfvrsn=99028107_8